Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcare conferences:

Citi's 2023 18^th Annual BioPharma Conference

Date:	Thursday, September 7, 2023
Time:	8:00AM ET
Webcast:	Click here

H.C. Wainwright 25^th Annual Global Investment Conference

Date:	Tuesday, September 12, 2023
Time:	2:00PM ET
Webcast:	Click here

To schedule a 1x1 meeting with management, please contact your Corporate Access representative.

The webcasts of the presentations will be accessible for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors section.

About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com